Persis spends half of his time looking after children undergoing BMT clinically and half of his time on research.
Persis trained at some of the leading haematology institutes in the world including:
- The Hammersmith Hospital, where he gained his interest in leukaemia and BMT.
- The National Institutes of Health.
- Bethesda USA and St Jude Children’s Hospital, Memphis, USA, where he obtained his PhD and Baylor College of Medicine where he started working on Cell and Gene Therapy.
Persis has an outstanding record of translating cutting edge science into clinical benefit for patients and has played a key role in developing a world-class research programme on the BMT unit at GOSH.
His research work has focused on immunotherapy – using immune cells to prevent infections and leukaemic relapse after stem cell transplant.
He is currently leading two major clinical trials in these approaches with two more studies planned. In parallel with this, with his colleagues on the BMT Unit at GOSH, he has pioneered novel antibody-based conditioning regimens for children with genetic diseases of the immune system to reduce the need for intensive chemotherapy before bone marrow transplant.
He has published more than 80 papers in peer-reviewed journals and attracted over £9 million in research grants.